Medicare: CMS’s Use of Data Analytics to Identify and Prevent Fraud

Why It Matters

The analytics‑driven approach safeguards the Medicare trust fund and reduces unnecessary out‑of‑pocket costs for beneficiaries, while the new data‑sharing policy closes a costly loophole for supplemental payers.

Key Takeaways

• CMS analytics suspended payments for 15 providers in $4 B catheter scheme
• $11.9 B in potentially fraudulent Medicare payments prevented FY2022‑2024
• Payment suspensions contributed $2.58 B of the prevented amount
• Private payers now get CMS suspension data, cutting cost‑sharing risk
• State Medicaid agencies spent $196 K on cost‑sharing for the scheme

Pulse Analysis

The Centers for Medicare & Medicaid Services has turned data analytics into a frontline weapon against fraud in traditional Medicare. By scanning millions of claims for spikes, abnormal billing patterns and provider‑level anomalies, CMS can flag emerging schemes before payments are made. The system feeds directly into the agency’s program‑integrity contractors, generating investigative leads that have already resulted in the suspension and eventual revocation of 15 providers tied to a $4 billion urinary‑catheter fraud. This proactive approach marks a shift from reactive audits to continuous, algorithm‑driven monitoring.

GAO’s analysis shows that CMS’s analytics‑driven actions prevented roughly $11.9 billion in potentially fraudulent payments across fiscal years 2022‑2024. The bulk of that savings came from payment suspensions ($2.58 billion) and revocations/deactivations ($7.96 billion), while automated pre‑payment denials and over‑payment recoveries added smaller but still meaningful contributions. By intercepting fraudulent claims early, the agency not only protects the Medicare trust fund but also reduces downstream costs for beneficiaries, who would otherwise shoulder cost‑sharing on illegitimate services. The magnitude of these figures underscores how technology can translate into tangible fiscal stewardship.

A notable development in late 2025 was CMS’s decision to share provider‑payment suspension data with supplemental payers, including private insurers and state Medicaid programs. Previously, these entities often covered beneficiary cost‑sharing on fraudulent claims, as illustrated by the $196 k paid by state Medicaid agencies for the catheter scheme and tens of millions potentially disbursed by private plans. Enhanced transparency aims to close that loophole, but it also raises questions about data privacy, timeliness and the capacity of private payers to act on the information. Ongoing collaboration and refined analytics will be essential to sustain fraud‑prevention gains and extend them across the broader health‑care payment ecosystem.